The sales are trivial relative to market cap and follow derivative exercises, suggesting tax-related or routine portfolio diversification rather than a negative signal. Monitor next 10-Q for any change in insider selling patterns or material ownership reductions.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $42.97entry
- T+1 · 7d ago −1.33%α −0.96% · $42.40
- T+5 · 15h ago −0.93%α +0.76% · $42.57
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Teva insiders, including a senior executive (Sabag Mark, See Remarks), sold shares in open-market transactions totaling $2.29M in the days following the company's Q3 2026 earnings beat and raised guidance. The sales are not under 10b5-1 plans and represent 0.005% of market cap, a trivial amount relative to the $48.8B valuation.
Key Financial Metrics
Key Facts
- Two insiders executed open-market sales (code S) totaling $2.29M, none under 10b5-1 plans
- Sabag Mark sold 46,000 shares at $41.93 for $1.93M on 2026-11-05
- Bergwerk Dov sold 17,505 shares at $41.72 for $730K and 8,755 shares at $41.72 for $365K on 2026-11-04
- Sales occurred 1-2 days after Teva reported Q3 2026 non-GAAP EPS of $0.86 (beat consensus by 19.4%) and revenue of $4.395B (above $4.23B consensus)
- Total sales represent 0.005% of Teva's $48.8B market cap, well below the 0.1% materiality threshold
- Both insiders also exercised derivatives at lower prices ($0-$34.9) on the same days, indicating the sales were likely to cover tax obligations or monetize option exercises
Financial Impact
Total open-market sales of $2.29M, representing 0.005% of market cap
Risk Factors
- Insider sales after a strong earnings beat could indicate management's view that the stock is fairly valued or that near-term upside is limited
- The sales are not under 10b5-1 plans, increasing the potential for information-based trading
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-TEVA-1793999058209 |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Viewing Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers